Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Subscribe To Our Newsletter & Stay Updated